PIK3CB and breast cancer: Nevertheless, most of the current phase III PI3K inhibitor clinical trials are investigating endocrine therapy-resistant advanced BC by combining PI3Ki with endocrine therapy, which has a synergistic effect and may help reverse endocrine therapy resistance.